Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
November 05, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common...
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
November 03, 2020 20:26 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing...
Global Cell Therapy Market and Technology Forecast 2020-2028
November 03, 2020 13:08 ET
|
Research and Markets
Dublin, Nov. 03, 2020 (GLOBE NEWSWIRE) -- The "Global Cell Therapy - Market and Technology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The global revenue of the...
Cell Therapy Technologies Market, 2029
October 30, 2020 03:38 ET
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. The...
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
October 29, 2020 17:16 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing...
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
October 29, 2020 17:15 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data...
Immatics präsentiert präklinische Proof-of-Concept-Daten für seinen bispezifischen T-Zell-Rezeptor gegen MAGEA4/8
October 29, 2020 07:00 ET
|
Immatics N.V.
Präklinische Proof-of-Concept Daten für ersten bispezifischen T-Zell-Rezeptor IMA401 zeigen vollständige Remissionen transplantierter humaner Tumore in Mäusen sowie positive CMC-Eigenschaften. Die...
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
October 29, 2020 07:00 ET
|
https://immatics.com/
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics The...
Bone Therapeutics signe des accords avec Catalent pour optimiser la production du produit de thérapie cellulaire allogénique ALLOB
October 29, 2020 02:00 ET
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Catalent acquiert la chaine de production de thérapie cellulaire de Bone Therapeutics pour 12 M€ Signature en parallèle d’un accord d’approvisionnement entre Bone...
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
October 29, 2020 02:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for EUR 12 million Bone Therapeutics and Catalent shall enter into a supply agreement for...